Search research articles
Contact Us
Filters
Showing results (121-130 of 165) with videos related to
Page
of 17
Sort By:
Investigational New Drugs
|
August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs
|
January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002
Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 27, 2022
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)
Hidetoshi Hayashi, Kimio Yonesaka, Atsushi Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 20, 2013
Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma
Daichi Fujimoto, Keisuke Tomii, Takehiro Otoshi, et al.
Clinical Lung Cancer
|
February 22, 2021
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, et al.
Cardiovascular Intervention and Therapeutics
|
April 5, 2023
Prediction of the debulking effect of rotational atherectomy using optical frequency domain imaging: a prospective study
Tomoyo Hamana, Hiroyuki Kawamori, Takayoshi Toba, et al.
Cancer Research Communications
|
January 5, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
Makoto Nishio, Shuji Murakami, Hisato Kawakami, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning
Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)
Takashi Seto, Koichi Azuma, Takeharu Yamanaka, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 27, 2019
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
Toshihide Yokoyama, Hiroshige Yoshioka, Daichi Fujimoto, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 165) with videos related to
Sort By:
Page
of 17
Investigational New Drugs
|
August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs
|
January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002
Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 27, 2022
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)
Hidetoshi Hayashi, Kimio Yonesaka, Atsushi Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 20, 2013
Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma
Daichi Fujimoto, Keisuke Tomii, Takehiro Otoshi, et al.
Clinical Lung Cancer
|
February 22, 2021
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, et al.
Cardiovascular Intervention and Therapeutics
|
April 5, 2023
Prediction of the debulking effect of rotational atherectomy using optical frequency domain imaging: a prospective study
Tomoyo Hamana, Hiroyuki Kawamori, Takayoshi Toba, et al.
Cancer Research Communications
|
January 5, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
Makoto Nishio, Shuji Murakami, Hisato Kawakami, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning
Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)
Takashi Seto, Koichi Azuma, Takeharu Yamanaka, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 27, 2019
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
Toshihide Yokoyama, Hiroshige Yoshioka, Daichi Fujimoto, et al.
Page
of 17